GSK has ended development of camlipixant, its refractory chronic cough candidate, after mixed Phase 3 readouts failed to meet key goals across two studies (Calm-1 and Calm-2). While one dosing regimen showed statistically significant reductions in 24-hour cough frequency at week 12, the program did not replicate efficacy later in the trials, and key secondary endpoints missed thresholds. GSK brought camlipixant into its portfolio through the 2023 Bellus Health deal. The termination closes a potential late-cycle catalyst for GSK, while potentially shifting attention to competitors pursuing alternative targets in chronic cough. The decision is a notable reminder of how sensitive late-stage results can be to dosing regimens and endpoint behavior—especially in symptom-driven indications where trial design and diary-based outcomes can swing on statistical nuances.